Skip to content Skip to footer
Subscribe Now
Axsome
News

Axsome Therapeutics Reports Topline Data of P-III (PARADIGM) Trial of Solriamfetol for Major Depressive Disorder (MDD) regardless of Excessive Daytime Sleepiness (EDS)

Shots:Axsome reported topline data of PoC P-III (PARADIGM) trial assessing solriamfetol (300mg) vs PBO in MDD pts with severe EDS (ESS ≥16; n=51) & those without severe EDS (n=295)Trial showed no significant MADRS total score change (1EP) in the overall population. However, EDS pts saw depressive symptom improvements across MADRS total score, MADRS…
April 2, 2025

Read more

VIEWPOINTS_Robert Barrow_2023
VIEWPOINTS

MindMed’s CEO Robert Barrow Discusses Positive P-II Trial Data of Lysergide for Major Depressive Disorder

Shots:Robert spoke about the topline data from the P-II study evaluating Lysergide. The data was unleashed by MindMed collaborators at the University Hospital Basel and the University Hospital of PsychiatryThe data demonstrated significant, rapid, durable and beneficial effects of Lysergide and its potential to mitigate symptoms of MDD.  He also discussed how these…
August 29, 2023

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]